Related references
Note: Only part of the references are listed.Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Peter Campbell et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2017)
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Song Mu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line
Magdalena Kusaczuk et al.
TUMOR BIOLOGY (2016)
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Ludovica Morera et al.
CLINICAL EPIGENETICS (2016)
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Y. Shi et al.
ANNALS OF ONCOLOGY (2015)
Unmasking the Lung Cancer Epigenome
Steven A. Belinsky
ANNUAL REVIEW OF PHYSIOLOGY, VOL 77 (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Gabriele Greve et al.
BMC CANCER (2015)
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 inhibitors in SCLC
Helai P. Mohammad et al.
CANCER CELL (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid
Gabriele Greve et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Christine M. Fillmore et al.
NATURE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date
Daniel P. Mould et al.
MEDICINAL RESEARCH REVIEWS (2015)
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer
Frank P. Vendetti et al.
ONCOTARGET (2015)
Clinical Results of Hypomethylating Agents in AML Treatment
Marjan Cruijsen et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Effects of combined epigenetic therapy with histone methyltransferase EZH2 inhibitor 3-deazaneplanocin and histone deacetylase inhibitor SAHA on non-small cell lung cancer cells
Taichi Takashina et al.
CANCER RESEARCH (2014)
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2014)
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Bertrand Coiffier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer
Donatella Del Bufalo et al.
MOLECULAR CANCER (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
Noemi Reguart et al.
LUNG CANCER (2014)
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma
Hongdo Do et al.
SCIENTIFIC REPORTS (2014)
Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer
B. F. Chu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells
Shauna N. Vasilatos et al.
CARCINOGENESIS (2013)
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
A. Dasari et al.
INVESTIGATIONAL NEW DRUGS (2013)
A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer
Juan Sandoval et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung
A. Gomes et al.
Revista Portuguesa de Pneumologia (2013)
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms
A. Ali et al.
CELL DEATH & DISEASE (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
Erlotinib resistance in lung cancer: current progress and future perspectives
Joy Tang et al.
FRONTIERS IN PHARMACOLOGY (2013)
Epigenetic therapy of non-small cell ung cancer using decitabine (5-aza-2'-deoxycytidine)
Richard L. Momparler
FRONTIERS IN ONCOLOGY (2013)
Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells
Yi Huang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
William J. Harris et al.
CANCER CELL (2012)
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies
Julie Bauman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies
Jacques Fahy et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Samir E. Witta et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The role of histone demethylases in cancer therapy
Inga Hoffmann et al.
MOLECULAR ONCOLOGY (2012)
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells
Junko Kikuchi et al.
LUNG CANCER (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients
Joon Seon Song et al.
PATHOLOGY INTERNATIONAL (2012)
Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer
Tangfeng Lv et al.
PLOS ONE (2012)
DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity
Hak Jae Kim et al.
RADIATION ONCOLOGY (2012)
Secreted blood reporters: Insights and applications
Bakhos A. Tannous et al.
BIOTECHNOLOGY ADVANCES (2011)
Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model
Steven A. Belinsky et al.
CANCER RESEARCH (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
Claudia P. Miller et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
Yoshihiro Minamiya et al.
LUNG CANCER (2011)
Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
Valentina Zuco et al.
PLOS ONE (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
A decade of exploring the cancer epigenome - biological and translational implications
Stephen B. Baylin et al.
NATURE REVIEWS CANCER (2011)
Inhibition of Class IIb Histone Deacetylase Significantly Improves Cloning Efficiency in Mice
Tetsuo Ono et al.
BIOLOGY OF REPRODUCTION (2010)
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells
Sonja Mandl-Weber et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids
Shaoteng Han et al.
PLOS ONE (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells
Feng Zhang et al.
CANCER BIOLOGY & THERAPY (2009)
TNF and LTA Gene, Allele, and Extended HLA Haplotype Associations with Severe Dengue Virus Infection in Ethnic Thais
Sasijit Vejbaesya et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer A Wisconsin Oncology Network Phase II Study
Anne M. Traynor et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers
Yutaka Kondo
YONSEI MEDICAL JOURNAL (2009)
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer
Cesare Gridelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
Johan Vansteenkiste et al.
INVESTIGATIONAL NEW DRUGS (2008)
Global histone modifications predict prognosis of resected non-small-cell lung cancer
Fabrice Barlesi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Psammaplin A is a natural prodrug that inhibits class I histone deacetylase
Dong Hoon Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura
David S. Schrump et al.
CLINICAL CANCER RESEARCH (2006)
15th Annual Meeting of the working group Experimental Neuro-Oncology February 24-25th, 2006, Gottingen, Germany - Abstracts
[Anonymous]
PEDIATRIC BLOOD & CANCER (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
SE Witta et al.
CANCER RESEARCH (2006)
Epigenetic therapy of cancer: past, present and future
CB Yoo et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer
HJ Grote et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas
AK Virmani et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer
G Schwartsmann et al.
INVESTIGATIONAL NEW DRUGS (2000)
Share Paper
